Evidence map›Paper›PMID 29743087›Full record

Trial reportLipids in health and disease2018

Untargeted metabolomic on urine samples after α-lipoic acid and/or eicosapentaenoic acid supplementation in healthy overweight/obese women.

Ana Romo-Hualde, Ana E Huerta, Carlos J González-Navarro, Omar Ramos-López, María J Moreno-Aliaga, J Alfredo Martínez

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Lipids in health and disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01138774 (Cellular and Molecular Effects of Lipoic Acid and Eicosapentaenoic Acid), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01138774 nacompletednot on this map

Cellular and Molecular Effects of Lipoic Acid and Eicosapentaenoic Acid (EPA) on Adipose Tissue: Potential Application in Human Obesity

TypeinterventionalSponsorClinica Universidad de Navarra, Universidad de NavarraRan2010 to 2012Enrolled103ConditionsObesity, Body Fat, Insulin ResistanceArmsDouble blind dietary intervention with EPA and lipoic acid
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ana Romo-HualdeCentre for Nutrition Research, University of Navarra, Pamplona, Spain.
Ana E HuertaCentre for Nutrition Research, University of Navarra, Pamplona, Spain.
Carlos J González-NavarroCentre for Nutrition Research, University of Navarra, Pamplona, Spain.
Omar Ramos-LópezCentre for Nutrition Research, University of Navarra, Pamplona, Spain.
María J Moreno-AliagaCentre for Nutrition Research, University of Navarra, Pamplona, Spain.
J Alfredo MartínezCentre for Nutrition Research, University of Navarra, Pamplona, Spain. jalfmtz@unav.es.ORCID http://orcid.org/0000-0001-5218-6941
Universidad de Navarra · ESInstituto de Salud Carlos III · ESMadrid Institute for Advanced Studies · ES

Funding

Government of Spain AGL 2009-10873/ALI and BFU2012-36089
6 · The paper itself

Abstract

backgroundEicosapentaenoic acid (EPA) and α-lipoic acid (α-LA) have been investigated for their beneficial effects on obesity and cardiovascular risk factors. In the current research, the goal was to evaluate metabolomic changes following the dietary supplementation of these two lipids, alone or combined in healthy overweight/obese sedentary women following an energy-restricted diet. For this purpose, an untargeted metabolomics approach was conducted on urine samples using liquid chromatography coupled with time of flight mass spectrometry (HPLC-TOF-MS).

methodsThis is a short-term double blind placebo-controlled study with a parallel nutritional design that lasted 10 weeks. Participants were assigned to one of the 4 experimental groups [Control, EPA (1.3 g/d), α-LA (0.3 g/d) and EPA+α-LA (1.3 g/d + 0.3 g/d)]. All intervention groups followed an energy-restricted diet of 30% less than total energy expenditure. Clinically relevant biochemical measurements were analyzed. Urine samples (24 h) were collected at baseline and after 10 weeks. Untargeted metabolomic analysis on urine samples was carried out, and principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA) were performed for the pattern recognition and characteristic metabolites identification.

resultsUrine samples were scattered in the PCA scores plots in response to the supplementation with α-LA. Totally, 28 putative discriminant metabolites in positive ionization, and 6 in negative ionization were identified among groups clearly differentiated according to the α-LA administration. Remarkably is the presence of an ascorbate intermediate metabolite (one of the isomers of trihydroxy-dioxohexanoate, or dihydroxy-oxohexanedionate) in the groups supplemented with α-LA. This fact might be associated with antioxidant properties of both α-LA and ascorbic acid. Correlations between phenotypical parameters and putative metabolites of provided additional information on whether there is a direct or inverse relationship between them. Especially interesting are the negative correlation between ascorbate intermediate metabolite and asymmetric dimethylarginine (ADMA) and the positive one between superoxide dismutase (SOD) and α-LA supplementation.

conclusionsThis metabolomic approach supports that the beneficial effects of α-LA administration on body weight reduction may be partly explained by the antioxidant properties of this organosulfur carboxylic acid mediated by isomers of trihydroxy-dioxohexanoate, or dihydroxy-oxohexanedionate.

trial registrationClinicaltrials.gov NCT01138774 .

Indexed as

Adipose TissueAdultAntioxidantsCardiovascular DiseasesDietary SupplementsEicosapentaenoic AcidFemaleHealthy VolunteersHumansMaleMetabolomicsObesityOverweightRisk FactorsThioctic AcidWeight LossAntioxidantsEicosapentaenoic AcidThioctic AcidEicosapentaenoic acidMetabolomicObesityOverweightα-lipoic acid

Identifiers

PMID29743087
PMCPMC5941619
OpenAlexW2800730324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.